Regulatory News
Tuesday, November 29, 2016
BRIEF-Cytrx reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas
* Cytrx-Reports statistically significant updated results
from pivotal phase 3 trial of aldoxorubicin in patients with
second-line soft tissue sarcomas
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment